review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Marc Humbert | Q33113039 |
Joan Albert Barberà | Q38545039 | ||
Friedrich Grimminger | Q43857421 | ||
Ralph T Schermuly | Q46115021 | ||
Nicholas W Morrell | Q60960702 | ||
John H. Newman | Q90295091 | ||
P2093 | author name string | Luc Mouthon | |
Marlene Rabinovitch | |||
Kurt R Stenmark | |||
Evangelos D Michelakis | |||
Sonia C Flores | |||
Michael L Maitland | |||
Paul M Hassoun | |||
Jason X-J Yuan | |||
Peter Lloyd Jones | |||
Norbert F Voelkel | |||
Saadia Eddahibi | |||
P433 | issue | 1 Suppl | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | inflammation | Q101991 |
P304 | page(s) | S10-9 | |
P577 | publication date | 2009-06-01 | |
P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
P1476 | title | Inflammation, growth factors, and pulmonary vascular remodeling | |
P478 | volume | 54 |
Q40073930 | A 49-Year-Old Man with Subacute Respiratory Failure and Interstitial Lung Opacities |
Q37555401 | A case of pulmonary arterial hypertension associated with adult hemophagocytic lymphohistiocytosis |
Q34914604 | A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion |
Q37410202 | A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents |
Q35147704 | A low mortality model of chronic pulmonary hypertension in sheep |
Q91642428 | A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase |
Q49960027 | A novel piperidine identified by stem cell based screening attenuates pulmonary arterial hypertension via regulating BMP2 and PTGS2 levels |
Q30539790 | A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial |
Q33569395 | Activation of Notch signaling by short-term treatment with Jagged-1 enhances store-operated Ca(2+) entry in human pulmonary arterial smooth muscle cells |
Q35412448 | Activity of Ca -activated Cl channels contributes to regulating receptor- and store-operated Ca entry in human pulmonary artery smooth muscle cells |
Q38804583 | Adhesion Molecules: Master Controllers of the Circulatory System. |
Q35219809 | Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension. |
Q46280910 | Adventitial Fibroblast Nox4 Expression and ROS Signaling in Pulmonary Arterial Hypertension |
Q33909537 | Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension |
Q34250971 | Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension |
Q28238985 | Ambrisentan |
Q34319305 | An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension |
Q38039046 | An update on the use of ambrisentan in pulmonary arterial hypertension. |
Q83454280 | Antagonism of CXCR7 attenuates chronic hypoxia-induced pulmonary hypertension |
Q36130814 | Antibodies recognising sulfated carbohydrates are prevalent in systemic sclerosis and associated with pulmonary vascular disease |
Q38105550 | Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension |
Q47975583 | Apparent Aortic Stiffness in Children With Pulmonary Arterial Hypertension: Existence of Vascular Interdependency? |
Q36805200 | Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension |
Q35142695 | BMP pathway regulation of and by macrophages |
Q37776859 | BMP signaling in vascular development and disease |
Q38943124 | BMP4 inhibits PDGF-induced proliferation and collagen synthesis via PKA-mediated inhibition of calpain-2 in pulmonary artery smooth muscle cells |
Q38732718 | BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators |
Q36534321 | Blockade of Astrocytic Calcineurin/NFAT Signaling Helps to Normalize Hippocampal Synaptic Function and Plasticity in a Rat Model of Traumatic Brain Injury. |
Q33593640 | Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension |
Q37822722 | Bosentan for the treatment of adult pulmonary hypertension |
Q37393653 | Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies |
Q36999817 | CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension |
Q42020850 | CCR5 as a treatment target in pulmonary arterial hypertension |
Q36628843 | CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension |
Q64062342 | Caffeic Acid Phenethyl Ester Rescues Pulmonary Arterial Hypertension through the Inhibition of AKT/ERK-Dependent PDGF/HIF-1α In Vitro and In Vivo |
Q30429980 | Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease |
Q37139375 | Calpain-2 activates Akt via TGF-β1-mTORC2 pathway in pulmonary artery smooth muscle cells |
Q34508068 | Cardiopulmonary involvement in Puumala hantavirus infection |
Q44972307 | Cell permeability, migration, and reactive oxygen species induced by multiwalled carbon nanotubes in human microvascular endothelial cells |
Q23917422 | Cell permeability, migration, and reactive oxygen species induced by multiwalled carbon nanotubes in human microvascular endothelial cells |
Q51132724 | Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension. |
Q23917498 | Cerium oxide nanoparticles attenuate monocrotaline induced right ventricular hypertrophy following pulmonary arterial hypertension |
Q38812727 | Challenges and opportunities in treating inflammation associated with pulmonary hypertension |
Q44490545 | Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus |
Q34199837 | Chronic allergic inflammation causes vascular remodeling and pulmonary hypertension in BMPR2 hypomorph and wild-type mice |
Q51743683 | Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway. |
Q37628897 | Chronic obstructive sleep apnea accelerates pulmonary remodeling via TGF-β/miR-185/CoLA1 signaling in a canine model |
Q48140426 | Circulating angiopoietins in idiopathic pulmonary arterial hypertension |
Q36505843 | Circulating cytokines and growth factors in pediatric pulmonary hypertension |
Q35868734 | Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension |
Q47909446 | Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. |
Q37492625 | Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis. |
Q45374084 | Compromised T-Cell Immunity and Virus-like Structure in a Patient with Pulmonary Hypertension |
Q37088266 | Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. |
Q39345470 | Critical effects of epigenetic regulation in pulmonary arterial hypertension |
Q37540613 | Current challenges in pediatric pulmonary hypertension |
Q50976417 | Cyp2c44 gene disruption is associated with increased hematopoietic stem cells: implication in chronic hypoxia-induced pulmonary hypertension. |
Q51815285 | Cyp2c44-mediated decrease of 15-HETE exacerbates pulmonary hypertension. |
Q34518898 | Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease |
Q35835947 | Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension |
Q58087645 | Diaphragm Muscle Fiber Weakness in Pulmonary Hypertension |
Q36535586 | Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells |
Q37620501 | Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways |
Q37070077 | Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. |
Q90108921 | Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2α |
Q83995042 | Docosahexaenoic acid monoacylglyceride decreases endothelin-1 induced Ca(2+) sensitivity and proliferation in human pulmonary arteries |
Q26996078 | Drug treatment of pulmonary hypertension in children |
Q41166063 | Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation. |
Q37518410 | Effect of Perflubron-induced lung growth on pulmonary vascular remodeling in congenital diaphragmatic hernia |
Q33738592 | Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension |
Q42142797 | Effects of tetrahydrobiopterin oral treatment in hypoxia-induced pulmonary hypertension in rat. |
Q34021089 | Egr-1 expression during neointimal development in flow-associated pulmonary hypertension. |
Q51140742 | Elevated serum levels of soluble CD146 in patients with systemic sclerosis. |
Q37679940 | Emerging drugs for pulmonary hypertension |
Q89941214 | Endoplasmic reticulum stress and pulmonary hypertension |
Q36888302 | Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension |
Q39040020 | Endothelial cell signaling and ventilator-induced lung injury: molecular mechanisms, genomic analyses, and therapeutic targets. |
Q38873978 | Endothelial cell-specific activation of transforming growth factor-β signaling in mice induces cutaneous, visceral, and microvascular fibrosis |
Q43429643 | Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension. |
Q37866804 | Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension |
Q35684753 | Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells |
Q36963124 | Enhanced Ca(2+)-sensing receptor function in idiopathic pulmonary arterial hypertension |
Q36026281 | Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine |
Q35601475 | Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension |
Q36002233 | Erythropoietin Attenuates Pulmonary Vascular Remodeling in Experimental Pulmonary Arterial Hypertension through Interplay between Endothelial Progenitor Cells and Heme Oxygenase |
Q34524900 | Estrogens and Development of Pulmonary Hypertension: Interaction of Estradiol Metabolism and Pulmonary Vascular Disease |
Q51732363 | Exercise training in pulmonary arterial hypertension. |
Q34182389 | Fetal production of growth factors and inflammatory mediators predicts pulmonary hypertension in congenital diaphragmatic hernia |
Q33859158 | Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats |
Q92555286 | Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development |
Q90379507 | Formulation and Characterization of Solid Lipid Nanoparticles Loading RF22-c, a Potent and Selective 5-LO Inhibitor, in a Monocrotaline-Induced Model of Pulmonary Hypertension |
Q43538214 | Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension |
Q37707674 | Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension |
Q36317485 | Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension |
Q41283956 | Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension |
Q34591167 | Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats |
Q61895125 | Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar |
Q40972077 | HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension |
Q37867676 | HIV infection and pulmonary arterial hypertension. |
Q35208059 | HMGB1 promotes the development of pulmonary arterial hypertension in rats |
Q49249618 | Helicity and Vorticity of Pulmonary Arterial Flow in Patients With Pulmonary Hypertension: Quantitative Analysis of Flow Formations |
Q34920216 | Heme oxygenase-1 and inflammation in experimental right ventricular failure on prolonged overcirculation-induced pulmonary hypertension |
Q38859147 | Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension. |
Q40464742 | High Pulsatility Flow Induces Acute Endothelial Inflammation through Overpolarizing Cells to Activate NF-κB. |
Q36621780 | High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4 |
Q37139542 | Histone deacetylation contributes to low extracellular superoxide dismutase expression in human idiopathic pulmonary arterial hypertension |
Q42688359 | Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid |
Q46280825 | Hypoxia and Local Inflammation in Pulmonary Artery Structure and Function |
Q35412507 | Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-β. |
Q41852292 | ID3 contributes to the acquisition of molecular stem cell-like signature in microvascular endothelial cells: its implication for understanding microvascular diseases |
Q36527952 | IL-13 receptor α2-arginase 2 pathway mediates IL-13-induced pulmonary hypertension |
Q37281476 | IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells |
Q33555523 | IL-32 promotes angiogenesis |
Q58730399 | Identification of a low frequency missense mutation in MUC6 contributing to pulmonary artery hypertension by whole-exome sequencing |
Q41713745 | Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. |
Q54476060 | Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. |
Q37954724 | Imatinib mesylate for the treatment of pulmonary arterial hypertension |
Q26851508 | Immune and inflammatory mechanisms in pulmonary arterial hypertension |
Q36527847 | In vivo knockdown of intersectin-1s alters endothelial cell phenotype and causes microvascular remodeling in the mouse lungs |
Q34923343 | Increased Expression of Growth Differentiation Factor-15 in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension |
Q38317794 | Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension |
Q84641191 | Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension |
Q34357428 | Infections in the immunosuppressed host |
Q55155611 | Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. |
Q54595523 | Inhalation of Stachybotrys chartarum evokes pulmonary arterial remodeling in mice, attenuated by Rho-kinase inhibitor. |
Q35777179 | Inhibition of Excessive Cell Proliferation by Calcilytics in Idiopathic Pulmonary Arterial Hypertension |
Q35572413 | Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice |
Q33925122 | Inhibition of the Ca(2+)-sensing receptor rescues pulmonary hypertension in rats and mice |
Q26860314 | Interdisciplinary networks for the treatment of childhood pulmonary vascular disease: what pulmonary hypertension doctors can learn from pediatric oncologists |
Q92239221 | Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension |
Q35994814 | Interplay of macrophages and T cells in the lung vasculature |
Q35014605 | Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats |
Q43458362 | Iptakalim ameliorates monocrotaline-induced pulmonary arterial hypertension in rats |
Q37032248 | Iptakalim influences the proliferation and apoptosis of human pulmonary artery smooth muscle cells |
Q34897476 | Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension? |
Q37787547 | Key role of the RhoA/Rho kinase system in pulmonary hypertension |
Q33793407 | Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension |
Q26853496 | Leukotrienes in pulmonary arterial hypertension |
Q60722882 | Levosimendan attenuates pulmonary vascular remodeling |
Q35057088 | Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease, and drug action |
Q84513994 | Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension |
Q37150873 | Lung-specific RNA interference of coupling factor 6, a novel peptide, attenuates pulmonary arterial hypertension in rats. |
Q38007884 | Mast cells: an expanding pathophysiological role from allergy to other disorders |
Q36960275 | Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling |
Q30234727 | Mechanisms Underlying HIV Associated Non-infectious Lung Disease. |
Q89153101 | Mechanisms contributing to persistently activated cell phenotypes in pulmonary hypertension |
Q37892336 | Mechanisms of disease: pulmonary arterial hypertension. |
Q46435567 | Melatonin attenuates hypoxic pulmonary hypertension by inhibiting the inflammation and the proliferation of pulmonary arterial smooth muscle cells |
Q42173250 | Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. |
Q36752368 | Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension |
Q58592398 | Metabolism and Redox in Pulmonary Vascular Physiology and Pathophysiology |
Q33982509 | MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts |
Q34818972 | MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells |
Q32884516 | MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension |
Q37664516 | Microvolt T-wave alternans profiles in patients with pulmonary arterial hypertension compared to patients with left ventricular systolic dysfunction and a group of healthy volunteers |
Q34576173 | Modification of hemodynamic and immune responses to exposure with a weak antigen by the expression of a hypomorphic BMPR2 gene |
Q26991806 | Molecular mechanisms of pulmonary arterial remodeling |
Q37069397 | Morphological changes in small pulmonary vessels are associated with severe acute exacerbation in chronic obstructive pulmonary disease. |
Q47255437 | Moving beyond the "Allegory of the Cave" in the assessment of pulmonary arterial hypertension |
Q41201643 | Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism |
Q41853468 | New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis |
Q37724192 | New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation |
Q37669139 | Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension |
Q39106214 | Non-infectious pulmonary disorders in HIV. |
Q90032112 | Noninvasive wave intensity analysis predicts functional worsening in children with pulmonary arterial hypertension |
Q51462560 | Notch activation of Ca2+-sensing receptor mediates hypoxia-induced pulmonary hypertension. |
Q28596829 | Novel biomarkers for risk stratification in pulmonary arterial hypertension |
Q37215728 | Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. |
Q34305561 | Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats. |
Q35896190 | Obesity and pulmonary arterial hypertension: Is adiponectin the molecular link between these conditions? |
Q35798472 | Optical Coherence Tomography of Pulmonary Arterial Walls in Humans and Pigs (Sus scrofa domesticus). |
Q39411412 | Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength |
Q35412362 | Overview of current therapeutic approaches for pulmonary hypertension. |
Q35926109 | Oxidant signaling for interleukin-13 gene expression in lung smooth muscle cells |
Q37725468 | PPARgamma activation: a potential treatment for pulmonary hypertension |
Q37689190 | PPARgamma as a potential therapeutic target in pulmonary hypertension |
Q35235680 | Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner |
Q37879213 | Pediatric pulmonary arterial hypertension: current and emerging therapeutic options |
Q90420612 | Perspective: Pathobiological paradigms in pulmonary hypertension, time for reappraisal |
Q26859280 | Perspective: ambient air pollution: inflammatory response and effects on the lung's vasculature |
Q35673848 | Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag |
Q42282811 | Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment |
Q40303684 | Pim-1: A new biomarker in pulmonary arterial hypertension |
Q102331412 | Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling |
Q90625006 | Potential Contribution of Carotid Body-Induced Sympathetic and Renin-Angiotensin System Overflow to Pulmonary Hypertension in Intermittent Hypoxia |
Q37623819 | Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension |
Q44027694 | Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension |
Q58178283 | Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells |
Q37115093 | Protection of oral hydrogen water as an antioxidant on pulmonary hypertension |
Q88773887 | Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension |
Q54946092 | Pulmonary Arterial Hypertension and Insulin Resistance. |
Q58998388 | Pulmonary Hypertension Is a Probable NO/ONOO− Cycle Disease: A Review |
Q26744781 | Pulmonary Hypertension and Indicators of Right Ventricular Function |
Q28085572 | Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics |
Q34095714 | Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses |
Q51318362 | Pulmonary hypertension and Hashimoto's thyroiditis: does a relationship exist? |
Q34782622 | Pulmonary hypertension and the right ventricle-thinking outside the box (Third International Right Heart Failure Summit, part 1). |
Q43967338 | Pulmonary hypertension following haematopoietic stem cell transplantation for primary haemophagocytic lymphohistiocytosis |
Q36316371 | Pulmonary hypertension in patients with Martorell hypertensive leg ulcer: a case control study |
Q92282817 | Pulmonary hypertension in the global population of adolescents and adults living with HIV: a systematic review and meta-analysis |
Q37816401 | Pulmonary vascular disease associated with schistosomiasis |
Q36163044 | Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension |
Q91611159 | Pulmonary vascular mechanical consequences of ischemic heart failure and implications for right ventricular function |
Q39057104 | Pulmonary vascular remodeling in pulmonary hypertension |
Q46280803 | Reactive Oxygen Species in COPD-Related Vascular Remodeling |
Q38074770 | Reactive oxygen species as therapeutic targets in pulmonary hypertension. |
Q33803027 | Reconstructing sickle cell disease: a data-based analysis of the "hyperhemolysis paradigm" for pulmonary hypertension from the perspective of evidence-based medicine |
Q37139562 | Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. |
Q34718076 | Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells. |
Q38870144 | Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. |
Q97538437 | Relationship between compliance and pulmonary vascular resistance in pulmonary arterial hypertension |
Q38019769 | Relationships between vascular oxygen sensing mechanisms and hypertensive disease processes |
Q35665448 | Repeated exposure to Aspergillus fumigatus conidia results in CD4+ T cell-dependent and -independent pulmonary arterial remodeling in a mixed Th1/Th2/Th17 microenvironment that requires interleukin-4 (IL-4) and IL-10. |
Q38195160 | Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension? a brief review |
Q35725663 | Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement? |
Q36639482 | Right ventricular systolic pressure measurements in combination with harvest of lung and immune tissue samples in mice |
Q50969268 | Role of Nerve Growth Factor in Development and Persistence of Experimental Pulmonary Hypertension. |
Q91792991 | SGK1 Mediates Hypoxic Pulmonary Hypertension through Promoting Macrophage Infiltration and Activation |
Q35062885 | STIM2 Contributes to Enhanced Store-operated Ca Entry in Pulmonary Artery Smooth Muscle Cells from Patients with Idiopathic Pulmonary Arterial Hypertension |
Q41763006 | Safety and feasibility of obtaining wedged pulmonary artery samples and differential distribution of biomarkers in pulmonary hypertension |
Q33965866 | Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease. |
Q64098812 | Schistosome infection and its effect on pulmonary circulation |
Q37133810 | Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: Detailed study |
Q35484295 | Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis. |
Q36929766 | Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism |
Q34627552 | Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension |
Q41827194 | Selective inactivation of PTEN in smooth muscle cells synergizes with hypoxia to induce severe pulmonary hypertension |
Q34973575 | Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. |
Q44336945 | Serum Bcl-2 values in children with pulmonary hypertension. |
Q36108039 | Severe pulmonary hypertension: The role of metabolic and endocrine disorders |
Q34297770 | Sex Hormones and Vascular Protection in Pulmonary Arterial Hypertension |
Q54977617 | Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease. |
Q33568826 | Sex differences in the pulmonary circulation: implications for pulmonary hypertension |
Q37133785 | Signal transduction in the development of pulmonary arterial hypertension |
Q33868613 | Simvastatin as a treatment for pulmonary hypertension trial. |
Q37330089 | Single-cell mass cytometry for analysis of immune system functional states |
Q89578350 | Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension |
Q34611424 | Skeletal muscle abnormalities in pulmonary arterial hypertension. |
Q54469933 | Small platelet microparticle levels are increased in pulmonary arterial hypertension. |
Q92126836 | Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous |
Q38112038 | Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension |
Q34535086 | Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report |
Q39202902 | Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations |
Q36747273 | Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome |
Q37475033 | Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall |
Q48179384 | Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis |
Q33950086 | Systemic sclerosis-associated pulmonary arterial hypertension |
Q37995985 | Targeted approaches to the treatment of pulmonary hypertension. |
Q38038222 | Targeting PDGF pathway in pulmonary arterial hypertension |
Q42592575 | Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension |
Q42145272 | Targeting the adventitial microenvironment in pulmonary hypertension: A potential approach to therapy that considers epigenetic change |
Q27027610 | Tenascin-C in development and disease of blood vessels |
Q47389219 | Tetrahydrobiopterin (BH4 ): Targeting endothelial nitric oxide synthase as a potential therapy for pulmonary hypertension |
Q47648153 | The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry |
Q90084127 | The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension |
Q35665034 | The Effects of Antigen-Specific IgG1 Antibody for the Pulmonary-Hypertension-Phenotype and B Cells for Inflammation in Mice Exposed to Antigen and Fine Particles from Air Pollution |
Q38066657 | The Fra-2 transgenic mouse model of systemic sclerosis |
Q98770789 | The Role and Regulation of Pulmonary Artery Smooth Muscle Cells in Pulmonary Hypertension |
Q46236716 | The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Lung Architecture Remodeling |
Q33804336 | The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature |
Q52817379 | The Roles of Genetic Factors in Kawasaki Disease: A Systematic Review and Meta-analysis of Genetic Association Studies. |
Q45046014 | The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension |
Q91653814 | The Search for Disease-Modifying Therapies in Pulmonary Hypertension |
Q30473252 | The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options |
Q38112032 | The adventitia: Essential role in pulmonary vascular remodeling |
Q33788493 | The cancer theory of pulmonary arterial hypertension |
Q89941195 | The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers |
Q39294892 | The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension. |
Q39353707 | The first Keystone Symposia Conference on pulmonary vascular isease and right ventricular dysfunction: Current concepts and future therapies |
Q26992278 | The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension |
Q34356918 | The myriad essential roles of microRNAs in cardiovascular homeostasis and disease |
Q36644859 | The right ventricle: biologic insights and response to disease: updated |
Q38102555 | The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models |
Q37851851 | The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. |
Q39095141 | The role of nuclear factor of activated T cells in pulmonary arterial hypertension |
Q35517586 | The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype |
Q28359603 | Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension |
Q35038418 | Transfer of human hepatocyte growth factor reduces inflammation and prevents pulmonary arterial remodeling in monocrotaline-induced |
Q36049930 | Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells |
Q38349395 | Treating pulmonary hypertension in pediatrics |
Q41970043 | Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide |
Q41895695 | Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension |
Q37806153 | Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials |
Q35015952 | Tyrosine kinases inhibition by Imatinib slows progression in chronic anti-thy1 glomerulosclerosis of the rat |
Q35085796 | Unrecognized glucose intolerance is common in pulmonary arterial hypertension |
Q37898899 | Update on pulmonary vascular diseases 2010. |
Q36411210 | Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension |
Q35517559 | Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension |
Q37073847 | WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension |
Q40706456 | Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements |
Q30248878 | World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. |
Q35576738 | Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia |
Q95531492 | [A clinical analysis of 15 children with systemic lupus erythematosus accompanied by pulmonary hypertension] |
Q84016564 | [Innovation for the cure of pulmonary arterial hypertension] |
Q36788720 | mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects |
Search more.